New horizons in melanoma treatment: targeting molecular pathways.
作者信息
Soon Christopher W M, Algazi Alain P, Cha Edward N, Daud Adil I
出版信息
Ochsner J. 2010 Summer;10(2):93-8.
Abstract
摘要
相似文献
1
New horizons in melanoma treatment: targeting molecular pathways.黑色素瘤治疗的新视野：靶向分子途径
Ochsner J. 2010 Summer;10(2):93-8.
2
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.BRAF抑制剂治疗诱导产生的活性氧（ROS）重编程代谢过程，影响黑色素瘤细胞的生长。
Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y.
3
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.PRIMA-1（Met）（APR-246）介导的p53激活使（V600E/K）BRAF黑色素瘤对维莫非尼敏感。
Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.
4
Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.多种癌症相关通路的活性与BRAF突变相关，并可预测黑色素瘤细胞对BRAF/MEK抑制剂的耐药性。
Cell Cycle. 2014;13(2):208-19. doi: 10.4161/cc.26971. Epub 2013 Oct 29.
5
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.双重抑制人黑色素瘤中的细胞周期蛋白依赖性激酶抑制剂 CDKN2C 和 CDKN1A。
J Natl Cancer Inst. 2012 Nov 7;104(21):1673-9. doi: 10.1093/jnci/djs373. Epub 2012 Sep 20.
6
promoter mutation determines apoptotic and therapeutic responses of -mutant cancers to BRAF and MEK inhibitors: Achilles Heel.启动子突变决定了 - 突变型癌症对 BRAF 和 MEK 抑制剂的凋亡和治疗反应：阿喀琉斯之踵。
Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):15846-15851. doi: 10.1073/pnas.2004707117. Epub 2020 Jun 19.
7
HI-511 overcomes melanoma drug resistance targeting AURKB and BRAF V600E.HI-511 克服了黑色素瘤耐药性，针对 AURKB 和 BRAF V600E。
Theranostics. 2020 Aug 1;10(21):9721-9740. doi: 10.7150/thno.44342. eCollection 2020.
8
Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines.在甲状腺和黑色素瘤BRAFV600E细胞系中，多能性标志物受MEK抑制的诱导情况存在差异。
Cancer Biol Ther. 2016 May 3;17(5):526-42. doi: 10.1080/15384047.2016.1139230. Epub 2016 Feb 1.
9
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.黑色素瘤中 BRAF(V600E) 抑制的可逆和适应性耐药。
Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.
10
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.通过使用ganetespib靶向抑制Hsp90克服黑色素瘤中获得性BRAF抑制剂耐药性。
Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.
引用本文的文献
1
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.组织蛋白酶K在黑素细胞性病变的免疫组化诊断中的应用
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1132-9. eCollection 2014.
本文引用的文献
1
MEK1 mutations confer resistance to MEK and B-RAF inhibition.MEK1 突变导致对 MEK 和 B-RAF 抑制的抗性。
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6. doi: 10.1073/pnas.0905833106. Epub 2009 Nov 13.
2
Main roads to melanoma.通往黑色素瘤的主要途径。
J Transl Med. 2009 Oct 14;7:86. doi: 10.1186/1479-5876-7-86.
3
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.黑色素瘤中酪氨酸激酶组分析揭示了ERBB4中的复发性突变。
Nat Genet. 2009 Oct;41(10):1127-32. doi: 10.1038/ng.438. Epub 2009 Aug 30.
4
NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.NRG1/ERBB3 信号在黑素细胞发育和黑色素瘤中的作用：抑制分化和促进增殖。
Pigment Cell Melanoma Res. 2009 Dec;22(6):773-84. doi: 10.1111/j.1755-148X.2009.00616.x. Epub 2009 Jul 30.
5
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
6
ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).表皮生长因子受体（ErbB）酪氨酸激酶促进恶性黑色素瘤细胞的增殖：吉非替尼（ZD1839）对其具有抑制作用。
Melanoma Res. 2009 Jun;19(3):156-66. doi: 10.1097/CMR.0b013e32832c6339.
7
Molecular pathogenesis of cutaneous melanocytic neoplasms.皮肤黑素细胞肿瘤的分子发病机制
Annu Rev Pathol. 2009;4:551-79. doi: 10.1146/annurev.pathol.3.121806.151541.
8
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.转基因BRAFV600E小鼠中的黑素细胞痣样增生和黑色素瘤
Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.
9
Oncogenic Braf induces melanocyte senescence and melanoma in mice.致癌性Braf在小鼠中诱导黑素细胞衰老和黑色素瘤。
Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022.
10
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.Braf（V600E）与PTEN缺失共同作用诱导转移性黑色素瘤。
Nat Genet. 2009 May;41(5):544-52. doi: 10.1038/ng.356. Epub 2009 Mar 12.
Zotero 插件